Dementia is a progressive cognitive impairment that affects the activities of daily living. Alzheimer’s disease (AD) is the most common form of the dementia worldwide accounting for 60–80% of all dementia cases. With an estimated cost exceeding $290 billion in the USA, understanding and development of future therapeutic strategies is vital. In this perspective, we will be examining the current thinking of AD research and therapeutic strategies, while proposing a possible new direction for diagnosis, understanding, and treatment targets. Non-coding RNA accounts for the largest population of the human transcriptome. Long noncoding RNA (lncRNA) is a recent molecule of interest in the biomedical research which is non protein coding and is of length greater than 200 nucleotides. LncRNAs have been shown to play diverse roles within the cells such as posttranscriptional and posttranslational regulation, chromatin modulation, and protein complex organization. Given the flexible and diverse role in disease pathophysiology, lncRNAs may serve as novel therapeutic targets for diagnosis and treatment. Evidently, recent studies showed that dysregulation of lncRNA influences the clinical course of tumorigenesis, neurological disorders, cardiovascular disease, diabetes, and acquired immunodeficiency syndrome (Kazimierczyk et al., 2020). This indicates that lncRNA can provide a unique avenue of research and possible therapeutic targets in AD.
Doxtater, Kyle; Tripathi, Manish K.; and Moshahid Khan, Mohammad, "Recent advances on the role of long non-coding RNAs in Alzheimer’s disease" (2020). School of Medicine Publications and Presentations. 100.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Neural Regeneration Research
Immunology and Microbiology